A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer

Conclusion Treatment with single agent axitinib should be considered due to acceptable toxicity profile and favorable median overall survival compared to standard therapies.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research